Insider Monkey
Recursion Pharmaceuticals Rises as Positive Phase 1b/2 Trial Results for REC-4881 Validate AI-Driven Drug Discovery Platform
📈
AI Sentiment
Highly Positive
9/10
- Home
- RXRX
as of 01-02-2026 2:27pm EST
$4.19
+$0.12
+2.95%
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | SALT LAKE CITY |
| Market Cap: | 2.2B | IPO Year: | 2021 |
| Target Price: | $8.00 | AVG Volume (30 days): | 23.2M |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.78 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.79 - $12.36 | Next Earning Date: | 11-05-2025 |
| Revenue: | $43,689,000 | Revenue Growth: | -32.98% |
| Revenue Growth (this year): | 6.74% | Revenue Growth (next year): | 34.31% |
AI-Powered RXRX Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 20 hours ago
AI Recommendation
hold
Model Accuracy: 71.90%
71.90%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Recursion Pharmaceuticals Inc. (RXRX)
Taylor Ben R
Sell
Chief Financial Officer
RXRX Dec 29, 2025
Avg Cost/Share
$4.18
Shares
21,383
Total Value
$89,380.94
Owned After
761,550
SEC Form 4
Khan Najat
Sell
Chief R&D Commercial Officer
RXRX Dec 22, 2025
Avg Cost/Share
$4.41
Shares
124,403
Total Value
$548,592.35
Owned After
611,135
SEC Form 4
Gibson Christopher
Sell
Chief Executive Officer
RXRX Dec 19, 2025
Avg Cost/Share
$4.50
Shares
40,000
Total Value
$180,000.00
Owned After
913,839
SEC Form 4
Borgeson Blake
Sell
Director
RXRX Dec 2, 2025
Avg Cost/Share
$4.37
Shares
220,000
Total Value
$961,400.00
Owned After
6,869,863
SEC Form 4
Gibson Christopher
Sell
Chief Executive Officer
RXRX Nov 19, 2025
Avg Cost/Share
$4.16
Shares
40,000
Total Value
$166,400.00
Owned After
913,839
SEC Form 4
Gibson Christopher
Sell
Chief Executive Officer
RXRX Nov 4, 2025
Avg Cost/Share
$5.21
Shares
40,000
Total Value
$208,400.00
Owned After
913,839
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Taylor Ben R | RXRX | Chief Financial Officer | Dec 29, 2025 | Sell | $4.18 | 21,383 | $89,380.94 | 761,550 | |
| Khan Najat | RXRX | Chief R&D Commercial Officer | Dec 22, 2025 | Sell | $4.41 | 124,403 | $548,592.35 | 611,135 | |
| Gibson Christopher | RXRX | Chief Executive Officer | Dec 19, 2025 | Sell | $4.50 | 40,000 | $180,000.00 | 913,839 | |
| Borgeson Blake | RXRX | Director | Dec 2, 2025 | Sell | $4.37 | 220,000 | $961,400.00 | 6,869,863 | |
| Gibson Christopher | RXRX | Chief Executive Officer | Nov 19, 2025 | Sell | $4.16 | 40,000 | $166,400.00 | 913,839 | |
| Gibson Christopher | RXRX | Chief Executive Officer | Nov 4, 2025 | Sell | $5.21 | 40,000 | $208,400.00 | 913,839 |
Latest Recursion Pharmaceuticals Inc. News
RXRX Breaking Stock News: Dive into RXRX Ticker-Specific Updates for Smart Investing
Compare RXRX vs Leading Stocks
See how RXRX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "RXRX Recursion Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.